{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:30:50Z","timestamp":1793025050779,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["R01CA249981"],"award-info":[{"award-number":["R01CA249981"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA249981"],"award-info":[{"award-number":["R01CA249981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biallelic <jats:italic>TP53<\/jats:italic> inactivation is the most important high-risk factor associated with poor survival in multiple myeloma. Classical biallelic <jats:italic>TP53<\/jats:italic> inactivation has been defined as simultaneous mutation and copy number loss in most studies; however, numerous studies have demonstrated that other factors could lead to the inactivation of <jats:italic>TP53<\/jats:italic>. Here, we hypothesized that novel biallelic <jats:italic>TP53<\/jats:italic> inactivated samples existed in the multiple myeloma population. A random forest regression model that exploited an expression signature of 16 differentially expressed genes between classical biallelic <jats:italic>TP53<\/jats:italic> and <jats:italic>TP53<\/jats:italic> wild-type samples was subsequently established and used to identify novel biallelic <jats:italic>TP53<\/jats:italic> samples from monoallelic <jats:italic>TP53<\/jats:italic> groups. The model reflected high accuracy and robust performance in newly diagnosed relapsed and refractory populations. Patient survival of classical and novel biallelic <jats:italic>TP53<\/jats:italic> samples was consistently much worse than those with mono-allelic or wild-type <jats:italic>TP53<\/jats:italic> status. We also demonstrated that some predicted biallelic <jats:italic>TP53<\/jats:italic> samples simultaneously had copy number loss and aberrant splicing, resulting in overexpression of high-risk transcript variants, leading to biallelic inactivation. We discovered that splice site mutation and overexpression of the splicing factor <jats:italic>MED18<\/jats:italic> were reasons for aberrant splicing. Taken together, our study unveiled the complex transcriptome of <jats:italic>TP53<\/jats:italic>, some of which might benefit future studies targeting abnormal <jats:italic>TP53<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/s41408-023-00919-2","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:02:23Z","timestamp":1694419343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Enze","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Sudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Jaouadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-6941","authenticated-orcid":false,"given":"Mohammad","family":"Abu Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","volume":"103","author":"J Caers","year":"2018","unstructured":"Caers J, Garderet L, Kortum KM, O\u2019Dwyer ME, van de Donk N, Binder M, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018;103:1772\u201384.","journal-title":"Haematologica"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.V92.3.802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802\u20139.","journal-title":"Blood"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56\u201365.","journal-title":"Blood"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica 2017;102:e364\u2013e7.","journal-title":"Haematologica"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","volume":"133","author":"A Thakurta","year":"2019","unstructured":"Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 2019;133:1217\u201321.","journal-title":"Blood"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"919_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021;12:293.","journal-title":"Nat Commun"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood 2016;128:1735\u201344.","journal-title":"Blood"},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"919_CR13","first-page":"2901","volume":"141","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood 2023;141:2901\u201311.","journal-title":"Blood"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/leu.2014.102","volume":"28","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014;28:2066\u201374.","journal-title":"Leukemia"},{"key":"919_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ajh.26507","volume":"97","author":"EA Rojas","year":"2022","unstructured":"Rojas EA, Corchete LA, De Ramon C, Krzeminski P, Quwaider D, Garcia-Sanz R, et al. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. Am J Hematol. 2022;97:700\u201310.","journal-title":"Am J Hematol"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat biotechnology. 2013;31:213\u20139.","journal-title":"Nat biotechnology"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, K\u00e4llberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15:591\u20134.","journal-title":"Nat Methods"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41587-021-00861-3","volume":"39","author":"DP Cooke","year":"2021","unstructured":"Cooke DP, Wedge DC, Lunter G. A unified haplotype-based method for accurate and comprehensive variant calling. Nat Biotechnol. 2021;39:885\u201392.","journal-title":"Nat Biotechnol"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-018-0023-9","volume":"1","author":"G Narzisi","year":"2018","unstructured":"Narzisi G, Corvelo A, Arora K, Bergmann EA, Shah M, Musunuri R, et al. Genome-wide somatic variant calling using localized colored de Bruijn graphs. Commun Biol. 2018;1:1\u20139.","journal-title":"Commun Biol"},{"key":"919_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy\u2010Moonshine A, et al. From FastQ data to high\u2010confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinforma. 2013;43:11.","journal-title":"Curr Protoc Bioinforma"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12064-012-0162-3","volume":"131","author":"GP Wagner","year":"2012","unstructured":"Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 2012;131:281\u20135.","journal-title":"Theory Biosci"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat methods. 2017;14:417\u20139.","journal-title":"Nat methods"},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids Res. 2015;43:e47.","journal-title":"Nucleic acids Res"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nbt.4020","volume":"35","author":"M Shao","year":"2017","unstructured":"Shao M, Kingsford C. Accurate assembly of transcripts through phase-preserving graph decomposition. Nat Biotechnol. 2017;35:1167\u20139.","journal-title":"Nat Biotechnol"},{"key":"919_CR26","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1093\/nar\/gkg563","volume":"31","author":"E Gasteiger","year":"2003","unstructured":"Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic acids Res. 2003;31:3784\u20138.","journal-title":"Nucleic acids Res"},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"D265","DOI":"10.1093\/nar\/gkz991","volume":"48","author":"S Lu","year":"2020","unstructured":"Lu S, Wang J, Chitsaz F, Derbyshire MK, Geer RC, Gonzales NR, et al. CDD\/SPARCLE: the conserved domain database in 2020. Nucleic Acids Res. 2020;48:D265\u2013D8.","journal-title":"Nucleic Acids Res"},{"key":"919_CR28","doi-asserted-by":"publisher","first-page":"W130","DOI":"10.1093\/nar\/gkx356","volume":"45","author":"J Wang","year":"2017","unstructured":"Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic acids Res. 2017;45:W130\u2013W7.","journal-title":"Nucleic acids Res"},{"key":"919_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"919_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"919_CR31","doi-asserted-by":"publisher","first-page":"D661","DOI":"10.1093\/nar\/gkx1064","volume":"46","author":"DN Slenter","year":"2018","unstructured":"Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. Nucleic Acids Res. 2018;46:D661\u2013D7.","journal-title":"Nucleic Acids Res"},{"key":"919_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:1\u201315.","journal-title":"BMC Bioinforma"},{"key":"919_CR33","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine learning in Python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"919_CR34","doi-asserted-by":"publisher","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","volume":"111","author":"S Shen","year":"2014","unstructured":"Shen S, Park JW, Lu Z-X, Lin L, Henry MD, Wu YN, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci USA. 2014;111:E5593\u2013E601.","journal-title":"Proc Natl Acad Sci USA"},{"key":"919_CR35","doi-asserted-by":"publisher","first-page":"e0118432","DOI":"10.1371\/journal.pone.0118432","volume":"10","author":"T Saito","year":"2015","unstructured":"Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS One. 2015;10:e0118432.","journal-title":"PLoS One"},{"key":"919_CR36","doi-asserted-by":"crossref","unstructured":"Jeni LA, Cohn JF, De La Torre F, editors. Facing imbalanced data--recommendations for the use of performance metrics. (IEEE, 2013).","DOI":"10.1109\/ACII.2013.47"},{"key":"919_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00535-013-0809-y","volume":"49","author":"Y Qu","year":"2014","unstructured":"Qu Y, Li J, Cai Q, Liu B. Hec1\/Ndc80 is overexpressed in human gastric cancer and regulates cell growth. J Gastroenterol. 2014;49:408\u201318.","journal-title":"J Gastroenterol"},{"key":"919_CR38","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1158\/1078-0432.CCR-11-0994","volume":"17","author":"P Wu","year":"2011","unstructured":"Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, et al. A gene expression\u2013based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res. 2011;17:6347\u201355.","journal-title":"Clin Cancer Res"},{"key":"919_CR39","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","volume":"34","author":"MJ Mason","year":"2020","unstructured":"Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, et al. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia 2020;34:1866\u201374.","journal-title":"Leukemia"},{"key":"919_CR40","doi-asserted-by":"publisher","first-page":"a026104","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6:a026104.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"919_CR41","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.3390\/ijms20246257","volume":"20","author":"T Anbarasan","year":"2019","unstructured":"Anbarasan T, Bourdon J-C. The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases. Int J Mol Sci. 2019;20:6257.","journal-title":"Int J Mol Sci"},{"key":"919_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/ng.3466","volume":"48","author":"X Zhou","year":"2016","unstructured":"Zhou X, Edmonson MN, Wilkinson MR, Patel A, Wu G, Liu Y, et al. Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet. 2016;48:4\u20136.","journal-title":"Nat Genet"},{"key":"919_CR43","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic acids Res. 2019;47:D766\u2013D73.","journal-title":"Nucleic acids Res"},{"key":"919_CR44","doi-asserted-by":"publisher","first-page":"e969136","DOI":"10.4161\/23723548.2014.969136","volume":"1","author":"JC Bourdon","year":"2014","unstructured":"Bourdon JC. p53 isoforms change p53 paradigm. Mol Cell Oncol. 2014;1:e969136.","journal-title":"Mol Cell Oncol"},{"key":"919_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154\u201360.","journal-title":"Cell Death Differ"},{"key":"919_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-019-0141-3","volume":"8","author":"J Smeby","year":"2019","unstructured":"Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, et al. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis 2019;8:1\u20138.","journal-title":"Oncogenesis"},{"key":"919_CR47","doi-asserted-by":"publisher","first-page":"E3287","DOI":"10.1073\/pnas.1321640111","volume":"111","author":"S Senturk","year":"2014","unstructured":"Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, et al. p53\u03a8 is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci USA. 2014;111:E3287\u2013E96.","journal-title":"Proc Natl Acad Sci USA"},{"key":"919_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2017.03.013","volume":"396","author":"H K\u0119dzierska","year":"2017","unstructured":"K\u0119dzierska H, Piekie\u0142ko-Witkowska A. Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 2017;396:53\u201365.","journal-title":"Cancer Lett"},{"key":"919_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4161\/rna.20146","volume":"9","author":"MF Jones","year":"2012","unstructured":"Jones MF, Lal A. MicroRNAs, wild-type and mutant p53: more questions than answers. RNA Biol. 2012;9:781\u201391.","journal-title":"RNA Biol"},{"key":"919_CR50","doi-asserted-by":"publisher","first-page":"15123","DOI":"10.1074\/jbc.C300054200","volume":"278","author":"S Sato","year":"2003","unstructured":"Sato S, Tomomori-Sato C, Banks CAS, Sorokina I, Parmely TJ, Kong SE, et al. Identification of Mammalian Mediator Subunits with Similarities to Yeast Mediator Subunits Srb5, Srb6, Med11, and Rox3* 210. J Biol Chem. 2003;278:15123\u20137.","journal-title":"J Biol Chem"},{"key":"919_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.cell.2009.03.010","volume":"137","author":"MJ Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz MJ, Santangelo MSP, Paronetto MP, de la Mata M, Pelisch F, Boireau S, et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009;137:708\u201320.","journal-title":"Cell"},{"key":"919_CR52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1101\/gr.111070.110","volume":"21","author":"JY Ip","year":"2011","unstructured":"Ip JY, Schmidt D, Pan Q, Ramani AK, Fraser AG, Odom DT, et al. Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res. 2011;21:390\u2013401.","journal-title":"Genome Res"},{"key":"919_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/gcc.20899","volume":"50","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, et al. The clinical impact and molecular biology of del (17p) in multiple myeloma treated with conventional or thalidomide\u2010based therapy. Genes Chromosomes Cancer. 2011;50:765\u201374.","journal-title":"Genes Chromosomes Cancer"},{"key":"919_CR54","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood.2020008346","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J, Perrot A, Caillot D, Belhadj K, Hulin C, Leleu X, et al. del (17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137:1192\u20135.","journal-title":"Blood"},{"key":"919_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood-2021-151495","volume":"138","author":"S Thibaud","year":"2021","unstructured":"Thibaud S, Etra A, Subaran R, Soens Z, Newman S, Chen R, et al. Pathogenic germline variants in multiple myeloma. Blood 2021;138:399.","journal-title":"Blood"},{"key":"919_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.molcel.2011.12.022","volume":"45","author":"Y Huang","year":"2012","unstructured":"Huang Y, Li W, Yao X, Lin Q-J, Yin J-W, Liang Y, et al. Mediator complex regulates alternative mRNA processing via the MED23 subunit. Mol Cell. 2012;45:459\u201369.","journal-title":"Mol Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00919-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:03:57Z","timestamp":1700492637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00919-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00919-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.A.W. received unrelated research support from Bristol\u2013Myers Squibb and Genentech and has received consulting fees from Genentech and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}